Introduction
Mycobacterium tuberculosis (Mtb) is the causative agent of tuberculosis (TB). While infection with Mtb may result in active disease, in most cases the bacteria persist in the infected host without open signs of disease [1] . The different outcomes of exposure to Mtb, active TB, latent TB or no disease, are known to depend to a large extent on the interplay between the invading Mtb and the host immune system.
Both innate and acquired branches of the immune response are essential in the battle against Mtb [2, 3] . Importantly, the very first steps of the innate immune response are crucial to modulate the overall innate as well as the acquired immune response [4] . Mtb cell wall components exhibit important specific pathogen-associated molecular patterns (PAMPs); the innate immune response is initiated upon recognition of these molecules by pattern recognition receptors (PRRs), expressed mostly by macrophages (M4s) and dendritic cells (DCs). Several classes of PRRs have been implicated in the recognition of Mtb, including Toll-like receptors (TLRs) and Ctype lectin receptors (CLRs), such as DC-specific intercellular adhesion molecule-3 grabbing nonintegrin (DC-SIGN) [5] . There are several TLR and non-TLR PRRs involved in activation of M4s and DCs by Mtb. Among these, an impressive body of data shows the importance of TLR2, while reports on the involvement of other TLRs are still controversial [6e9] . Via TLRs and/or nucleotide-binding oligomerization domain receptors, intracellular signals are induced in M4s and DCs, initiating a local immune response leading to cytokine production and increased numbers of M4s and DCs in the infected tissue and draining lymph nodes. Following activation by cytokines and innate receptor agonists, infected M4s elicit direct bactericidal effector functions. DCs are known to phagocytose the bacteria in infected tissues , migrate to draining lymph nodes, and initiate the adaptive immune response by priming naïve T and B lymphocytes. Here, the maturation/activation state of DCs has been shown to play an important role in their response to infection and in the subsequent acquired immune response [10] .
Several cell wall associated mycobacterial glycolipids/lipoglycans e play a crucial role in the immunomodulation induced by
Mtb by eliciting distinct immune responses and activating/ repressing different immune cascades [11] . In particular lipoarabinomannan (LAM) has been studied for its immunomodulatory properties by numerous researchers. In addition to LAM, its precursors lipomannan (LM) [12e14] and phosphatidyl-myo-inositol mannosides (PIMs) [12e15] have been shown to have potent modulatory effects in vitro on cells of the immune system ( Figure 1 ). LAM, LM and PIMs are all prevalent components of the mycobacterial cell wall [16] . In addition to the LAM/LM/PIM family of molecules the cell wall is composed of other lipids and glycolipids such as trehalose containing and phenolic glycolipids, as well as glyco-and lipo-proteins, which also contribute to the immune response. However these will not be the focus of this review.
In 1989 the major cell wall associated glycolipid, mannosecapped LAM (ManLAM) from Mtb was reported to stimulate the release of pro-inflammatory cytokines such as tumour necrosis factor (TNF) from human and murine M4s [17] . However, in subsequent publications, the reported effects of ManLAM on M4s and DCs were not consistent, in respect to activation and release of proinflammatory cytokines, such as interleukin (IL)-12 and IL-6 (Table 1) , and expression of co-stimulatory (CD80, CD86) and antigen presenting molecules (MHC class II) ( Table 2 ). In summary, over the last three to four decades many conflicting results on the immunomodulatory effects of ManLAM and other LAMs and their precursor molecules have accumulated, leaving the scientific community in confusion.
These and other complex and sometimes contradictory reported actions of Mtb associated cell wall glycolipids prompted us to analyse the possible reasons underlying those discrepant results. A deep analysis of the literature revealed that several factors contribute to such diverse effects and also to the lack of consistency. On one hand there are very important differences between the immunomodulatory abilities of the different glycolipids (PIM, LM, LAM and ManLAM and potentially others) present in the Mtb cell wall [18] ; the analysis of the different molecules separately is essential if one aims to understand how Mtb glycolips modulate the host immune response. On the other hand, the same glycolipid may vary in composition between distinct Mtb complex strains. In addition to this inherent glycolipid diversity, differences in the protocols used to perform the experiments might also have contributed to the lack of consistency in the published results. Differences include variables associated with distinct protocols to grow the bacteria (which have a strong influence on the composition of the bacterial cell wall glycolipids); diverse strategies to isolate the distinct glycolipids (which have an effect on the composition/structure of the isolated glycolipids) compounded by the amphiphilic/amphipathic nature of LM and LAM; differences in the immune cells used (M4s, monocytes and DC; mouse or human origin); and on the protocols used to isolate/stimulate/differentiate e Lipoglycan or lipoglycoconjugate might be chemically more accurate terms to describe LM and LAM, however since all are based on a mannosylphosphatidylinositol anchor, the generic term glycolipid may be applicable to all three ligand classes. For the sake of simplicity we will use the term glycolipid. [29,42,88e92] . There is some question as to the exact attachment points of the arabinan portions to the LM core in LAM, and the number of Araf residues and their arrangement can vary. these cells (which impact on the activation/maturation status of the cells, receptor (PPR) equipment and signalling pathways that are active). To all of these variables in the protocols used by distinct laboratories one needs still to consider the use of preparations of allegedly pure specific glycolipids that have been shown to be contaminated with other glycolipids or even other components [18] .
In an attempt to bring some clarification to this important issue we here review the reported effects of the three major mycobacterial cell wall glycolipids, ManLAM, LM and PIMs on the maturation and cytokine profiles of murine and human M4s and DCs, dissecting the differences associated with the structure/composition of these molecules as well as the discrepancies that might result from experimental conditions. Although this review focuses on the effects of glycolipids on M4s and DCs it is of relevance to stress that these molecules also exert effects on other important cells in the immune response against Mtb. This is the case for neutrophils that in combination with alveolar M4s are recognized as the first line of defence against pulmonary TB. Several studies show how the very initial response of neutrophils, in particular the ability to trigger apoptosis, influences the overall subsequent immune response [19] . Most of these studies address how neutrophils respond to whole bacteria, which seems necessary to trigger apoptosis of neutrophils [20] . However, purified glycolipids, in particular LAM, but not PIM, have been shown to be sufficient to induce other functions, namely TRAIL release by neutrophils [21] . T cells have been mostly investigated as the main players of the acquired immune response triggered by Mtb components presented in the context of antigen presenting molecules. However, purified glycolips are also known to directly influence T cells. LAM and/or more specifically mannose capped lipoarabinomannan (ManLAM), have been shown to directly inhibit the activation/proliferation of T cells [22e24] and to specifically modulate the cytokine profile released by these cells [25] .
LAMs are found in the cell wall of all mycobacterial species [26] . Generally they present a tripartite structure composed of an acylated mannosylphosphatidylinositol (MPI) anchor, attached to a poly-mannosyl backbone with arabinan branches, and different capping motifs [16, 27] (Figure 1 ). ManLAM is most abundant in slowly growing pathogenic species of the Mtb complex, i.e. organisms causing TB, in particular Mtb and Mycobacterium bovis [26, 28] but also attenuated M. bovis, i.e. Bacillus CalmetteeGu erin M. bovis (BCG). Other structural variants of LAM are PILAM (formerly called AraLAM [29] ) with arabinan chains terminated with phospho-inositol motifs, such as in Mycobacterium smegmatis [30] or AraLAM devoid of any capping motifs, such as in Mycobacterium chelonae, are typical of less pathogenic mycobacteria, [29] .
PIMs and LM are direct precursors of LAM; the phosphatidylinositol dimannosides (PIM 2 ) and hexamannosides (PIM 6 ) are the two most abundant classes of PIMs found in BCG and Mtb H37Rv. PIM 2 gives rise to the highly mannosylated LM molecule, which is further extended by the arabinan domain to form LAM. They are non-covalently attached to the plasma membrane through their phosphatidyl-myo-inositol anchor, and extend to the exterior of the cell wall [16] although there is evidence for partial placement in the mycolic acid-rich mycobacterial outer membrane [31, 32] . By contrast PIM 6 appears to be an end product [16] . LAM/LM are not single chemical entities and the basis of their structural heterogeneity may be due to variations in e.g. the number and nature of the acyl groups, length and branching of the mannan core, or arabinan component [33] . LAM, LM and PIM exhibit various acyl forms, for example the "PIM 6 family" of BCG corresponds to a mixture of 10 and 12 acylated forms [14] .
Cell wall glycolipids play a part in the distinct immune response elicited by different Mtb-complex strains
It is becoming increasingly apparent that different Mtbcomplex strains induce different responses by the host's immune cells [34, 35] . For example the magnitude and patterns of the cytokine responses in Mtb infected M4s is highly mycobacterial strain-dependent [7, 36, 37] . Human alveolar M4s infected with the virulent laboratory strain Mtb H37Rv or M. bovis produce more TNF than those infected with the more attenuated Mtb H37Ra strain or with BCG [38] . In turn, human M4s infected with virulent clinical Mtb isolates produce more TNF than those infected with Mtb H37Rv [37] . Strains of the Mtb Beijing lineage, defined by specific RD deletions, are differentially recognized by TLRs and trigger different immune responses [36] . The mechanism responsible for these strain-related differences is most likely multi-factorial, but may in part be dependent on the different nature and relative amounts of the cell wall-associated glycolipid molecules produced by different mycobacterial strains. Small but important differences in glycolipid structure between individual Mtb-complex strains may account for important differences in the immune response [14, 33, 39] . It has, for example, been shown that ManLAMs from H37Rv, Mtb Erdman and BCG differ in structural aspects [28] such as mannosyloligosaccharide capping content [40] , which might be important for biological function. Mtbcomplex strains containing truncated and more branched forms of mannose-capped ManLAM result in their low association with the M4 mannose receptor [39] . Thus LAM from Mtb H37Rv and BCG were reported to be heterogeneous with respect to arabinan and mannan domains and to differ in abundance of acyl-isoforms [41] . Variations in mannose-capped terminal arabinan motifs have been observed in LAMs from clinical isolates of Mtb [42] , which may well be responsible for the different biological activities. Cytokine expression is influenced by the acylation state of LM ligands [43] and there is a relationship between the overall charge of the ManLAM molecule and its capacity to stimulate the production of interferon-g (IFN-g) in different CD1b-restricted Tcell lines [44] . There are also differences in the ability of LAM from different Mtb strains (Erdman, H37Rv and H37Ra) to mediate adherence to M4s [45] .
Culture conditions of the Mtb-complex strains have been shown to affect the composition of the isolated glycolipids [46, 47] . Hence, in order to dissect the role of mycobacteria derived molecules on the innate immune responses not just the choice of mycobacterial strain for isolation of the glycolipids is of utmost importance but also the protocol used to grow the bacteria and isolate the glycolipids (discussed in more detail ahead).
M4 activation/maturation and cytokine production upon exposure to ManLAM from various sources
ManLAMs purified from Mtb complex were, in early studies in the late 1980s early 1990s, found to stimulate the production of pro-inflammatory cytokines, in particular TNF, by both human [17, 48] and mouse [17,49e51] M4s (Table 1) . However, the reported magnitude of the TNF secretion varied greatly between studies. ManLAM has also been reported to affect other M4 functions, such as inhibition of various IFN-g mediated microbicidal and tumoricidal activities [52e54], but it has also been reported that ManLAM can trigger the microbicidal activity of IFN-g-primed M4s [50] .
In the report by Moreno et al. [17] in 1989 treatment of the ManLAM with alkali greatly reduced the TNF-secreting activity, suggesting that O-acyl groups were involved. A few years later ManLAM derived from the "virulent" laboratory Mtb strain Erdman was reported to be a weak stimulator of a pro-inflammatory response in respect to TNF production [49] and stimulation of NFkB [55] in mouse M4s compared to LAM isolated from the so called "avirulent" H37Ra laboratory strain. Some of the discordant information about the effect of ManLAM on the induction of a proinflammatory response by M4s apparently stem from these early papers.
Erdman ManLAM induces low/no pro-inflammatory response
ManLAM prepared from the Mtb Erdman strain [56] was used in many of the early studies analyzing M4 activation (Table 2) and cytokine production ( Table 1) . Erdman ManLAM preparations were repeatedly reported to either fail to induce the production of TNF in mouse [49, 50, 57] M4s, or to produce very low amounts of TNF (Table 1) , not only compared to LAM (AraLAM, see ahead) prepared from the so called "avirulent" H37Ra laboratory strain [49e51,57] (see ahead) but also compared to Man-LAM from H37Rv [51] . When ManLAM preparations from the strains H37Rv and Erdman were examined side by side [51] , H37Rv ManLAM was found to induce higher amounts of TNF compared to that from Erdman [51] in murine peritoneal M4s. ManLAM from Erdman also failed to induce IL-12p40 in mouse M4s [58] . Reports suggest that IFN-g activation is needed to stimulate TNF production through stimulation of peritoneal M4s with Erdman ManLAM [50] , while in other studies bone marrow derived cells were unresponsive to Erdman ManLAM despite IFNg activation [57] .
The AraLAM that in early papers was said to be from H37Ra was from a rapid growing strain Part of the discordant results from the early in vitro experiments [13, 49, 50] stems from the fact that the AraLAM (without mannose cap, and a potent inducer of TNF) that in these early papers was said to stem from the "avirulent" attenuated H37Ra strain in fact came from a rapidly growing mycobacteria species, presumably M. smegmatis [28, 29] , in which LAM is not mannose-capped (while LAMs from both H37Rv and H37Ra are mannose capped) [29] . In general, LAM lacking mannose capping (AraLAM/PILAM) stimulates higher TNF production than ManLAM from Mtb-complex strains [59] , indicating that the amount of mannose capping may be responsible for the pro-inflammatory capacity of a particular strain. Indeed the Erdman Mtb strain is reported to be significantly more mannose-capped, compared to H37Rv [40] and H37Ra [29, 40] , which may be part of the explanation for its low/absent proinflammatory activity. However, although the loss of LAM mannose caps in a mutant of BCG induced a somewhat higher production of TNF in M4s, as compared to the wild type strain, it did not affect the production of TNF in DCs [60] . Neither did the lack of the mannose cap in a Mtb mutant affect its virulence in mice [60] an observation that deserves attention in the future.
ManLAM from Mtb H37Rv drives maturation/activation of human DCs
The interaction of ManLAM with DCs, in particular with human DCs, is less well studied than the interaction with M4s [61e63]. It was demonstrated that a highly purified H37Rv ManLAM was a potent activator of human DCs showing several similarities with LPS in respect to DC cytokine production and cell maturation profile [18] (Table 2 ). These observations are in agreement with the findings by Dulphy et al. [64] where DCs were activated with ManLAM from H37Rv, displaying a dose-dependent maturation phenotype, in terms of CD83 and CD86 expression but in contrast to the findings by Geijtenbeek et al. [63] and Wu et al. [65] where ManLAM did not induce DC maturation. The reason for this discrepancy is not clear but it could be hypothesized that also here strain-associated differences in the relative abundance of molecular forms of Man-LAM or/and degree of purity of the preparation used could contribute to the observed divergent effects on DC maturation.
Cytokine response of DCs stimulated by ManLAM
ManLAM from H37Rv was shown to induce a strong proinflammatory cytokine response in human DCs, manifested by TNF, IL-6, and IL-12 release [18] (Table 1) . Similar results were reported in a recent study using mouse cells, where ManLAM activated bone-marrow-derived DC were shown to produce pro-and anti-inflammatory cytokines via a C-type lectin receptor, Dectin-2 [66] . Thus ManLAM induces the production of TNF and IL-6 as well as the anti-inflammatory cytokine IL-10. In a study by Dulphy et al. [64] , ManLAM-activated DCs produced the pro-inflammatory cytokines IL-6 and IL-8 but at a lower amount compared with cells stimulated by LPS, as well as low amounts of IL-10 and the functional IL-12p70 heterodimer.
In an earlier study by Nigou et al. different types of ManLAM obtained from BCG were reported to have different stimulatory capacity [62] . While the cell wall-associated preparation, "parietal" ManLAM, was shown to induce TNF and IL-8 production, the cell membrane-associated "cellular" ManLAM preparation did not induce a clear production of TNF or IL-8 [62] . The "parietal" type was reported to be uniquely O-acylated and Man-capped to a larger extent than the "cellular" type [62] .
Considering its TNF stimulatory effect, the H37Rv ManLAM preparation investigated by Mazurek et al. [18] behaved as the "parietal" ManLAM used by Nigou et al. [62] ; however, one should keep in mind that more than 90% of ManLAM preparations from BCG consists of "cellular" ManLAM [62] . A potential reason for the discrepant results in terms of pro-inflammatory responses by ManLAM may be differences in the strains from which the ManLAM was isolated. Thus ManLAM derived from M. bovis was shown to induce pro-inflammatory cytokines in DCs at a much lower level than ManLAM from H37Rv [18] . The ManLAM used by Nigou et al. was from BCG [62] , while the ManLAMs used by Mazurek et al. [18] and Dulphy et al. [64] were from H37Rv (Table 1 ). Yet another reason could be differences in the type of DCs used and protocols to prepare these cells.
ManLAM has been reported to be unable to trigger IL-10 release from human blood monocytes [59] . However, ManLAM preparations from H37Rv induced IL-10 from human DCs in the study by Mazurek et al. [18] as well as in a study using mouse DC [66] . This was hardly surprising given that IL-10 is secreted in response to TLR ligation as well as to high levels of TNF and IL-6 [67] in a negative feedback manner.
Effect of ManLAM on LPS-activated M4s and DCs
The pro-inflammatory molecule LPS [68] is known to drive maturation of M4s [69] and DCs, and triggers production of proinflammatory cytokines [70] such as TNF, IL-6, and IL-12. For this reason the interaction between ManLAM and LPS has been studied, and also here the activity of various ManLAM preparations varies in different experimental setups (Table 3) . In early studies Erdman ManLAM was found to block subsequent LPS-induced M4 activation [50] . On the other hand a more recent study showed that H37Rv ManLAM potentiated the LPS-induced expression of CD80, but not the expression of CD86, or MHC II, and stimulated a moderate but significant increase of cytokine production (TNF, IL-6, and IL-12) in human DCs over that induced by LPS alone [18] . Similar observations for IL-12p35, IL-12p40, IL-6 and IL-10 were made by Gringhuis et al. [71] who found that the production of cytokines was increased when cells were treated with LPS together with ManLAM as compared to cells exposed to LPS alone [71] . The findings that H37Rv ManLAM provides additional stimuli to the LPS-induced cytokine secretion, resulting in the augmented cytokine output, suggests that different PRRs on human DCs may be involved in the ManLAM-as compared to LPS-driven cytokine responses.
In contrast with these results a paper by Nigou et al. reported that the "cellular" ManLAM preparation from BCG inhibited IL-12 secretion by human DCs when stimulated with LPS [61] . A similar negative effect was reported by Knutson et al. [72] making use of a monocyte cell line. Also reporting a negative effect the study by Geijtenbeek et al. [63] showed that Mtb ManLAM inhibited LPSinduced DC maturation.
Immunomodulation induced by LM and PIMs
LMs from different mycobacterial species have been reported to exhibit contradictory activities, both pro-inflammatory and antiinflammatory responses through TLR2-dependent and -independent pathways [7, 43, 73] (Table 4) . LM, including LM purified from H37Rv, has been shown to induce IL-12 production in a TLR-2 dependent manner [12] and also inhibit IL-12 production in a TLR-independent manner [7] . LM (from BCG and Mtb H37Rv) has been reported to be a strong inducer of TNF through a TLR2 dependent pathway [74] , but LM from H37Rv has been also reported to block TNF biosynthesis [75] . LM purified from M. chelonae and Mycobacterium kansasii has been described to induce TNF and IL-8 secretion through a CD14-TLR2-dependent mechanism [73] .
The LM activity appears to depend on the acylation degree [14] , on the length of the mannan chain building the mannopyranosyl backbone of LM [74] and to be determined by binding to TLR2 [74] .
PIM 2 and PIM 6 are the two most abundant classes of PIMs found in Mtb and BCG [76] . In earlier studies non-fractionated PIMs from H37Ra [15, 77] and PIM 6 from BCG [14] were reported to stimulate the production of TNF through TLR2 signalling in M4s [14, 15] (Table 5 ). According to the authors this effect depended on the presence of the lipid component of the molecule as de-acylation of PIM 6 abrogated the TNF production [14] . By contrast, in a recent report, PIM 2 and PIM 6 from BCG were reported to present antiinflammatory activities, inhibiting LPS-induced TNF, IL-12, IL-6, but also inflammatory activities by inhibiting IL-10 production in mouse M4s through a TLR2-independent mechanism [76] . These effects were reported to depend on the acylation degree; di-and triacylated PIMs were strongly inhibitory, while tetra-acylated were less inhibitory, and mono-acylated PIMs were non inhibitory [76] .
The observations by Doz et al. of a prominent anti-inflammatory action of PIMs on murine M4s [76] were corroborated and extended by Mazurek et al. using human DCs [18] . In these studies PIM 2 and total PIM, isolated both from Mtb H37Rv and BCG, were reported to be potent inhibitors of the LPS-driven activation of human DCs [18] . PIMs reduced LPS-driven up-regulation of MHC II but did not modulate LPS-induced expression of the co-stimulatory molecules CD80 and CD86 [18] . In addition, PIMs also abrogated ManLAM-elicited augmentation of pro-inflammatory cytokine production (TNF, IL-6 as well as IL-12p40) in LPS-treated DCs [18] . Unlike ManLAM, PIMs alone did not affect surface expression of DC maturation markers (Table 5) . Thus, the inhibition of LPS-induced cytokine production does not seem to be caused by delayed maturation/activation of DCs but rather by a down-regulation of either transcription and/or secretion of those cytokines. PIMs from M. bovis showed inhibitory activity similar to that of PIMs from Mtb H37Rv [18] . This is consistent with the fact that the two differently acylated isoforms of PIM 2 and PIM 6 are simultaneously present in both Mtb H37Rv and BCG [78] . More recently synthetic PIM 1 and PIM 2 analogues were also shown to inhibit TNF and IL-12p40 expression induced by TLR2 or TLR4 pathways in murine M4s [76, 79] . PIM 1 and PIM 2 inhibited LPS-induced TNF release by a CD14-dependent pathway, while IL-12p40 inhibition was CD14 independent.
In conclusion there is clear evidence that certain PIMs from Mtb H37Rv, M. bovis and BCG are potent anti-inflammatory agents that inhibit the pro-inflammatory activity of both LPS and ManLAM.
Experimental factors potentially relevant for reported differences in immunomodulation of LAM, LM and PIM glycolipids
The immune response elicited in vitro by glycolipids is strongly dependent on the experimental conditions
The type and activation state as well as the origin of cells (human/animal) chosen for in vitro stimulation experiments may profoundly affect the final outcome. Bradbury and Moreno [51] examined the action of ManLAM on murine peritoneal and bone marrow derived M4s and found that only the former produced TNF in response to H37Rv ManLAM. In accordance, several preparations of ManLAM from Mtb H37Rv [7, 80] and Erdman [57, 80] failed to induce TNF production in murine bone marrow derived M4s. Presumably mouse bone marrow derived M4s are less "mature" or more naive than those derived from intraperitoneal sources [81] . Various methods of in vitro M4 maturation confer variable capacity for inflammatory responses [82] , and it could thus be speculated that M-CSF, used to propagate M4s from bone marrow, being a potent regulator of M4 receptors expression, affects the expression of ManLAM-recognizing receptors [83] . Molecules of the LAM/LM/PIM family have been reported to bind to and signal through various PPRs on host cells. Some of these molecules bind to TLR2 and/or other TLRs [6e8], while others, such as ManLAM, are thought to bind DC-specific C-type lectin DC-SIGN/ CD209 and mannose receptors and to deliver negative signals that interfere with TLR-mediated signalling [61] . Mycobacterial lipoglycans of the LAM/PIM family show a varying degree of TLR2-dependent pro-inflammatory activities [74] . Thus, since PPR expression is strongly influenced by the cells used and the protocol applied to prepare them, one need to pay special attention to this information when analyzing the data generated.
Other experimental factors that may influence results are e.g. time of exposure and amounts of ManLAM used in the treatment of cells as well as its presentation. Thus for example augmentation of LPS-induced TNF production was found after short stimulation (1e4 h) of M4s with ManLAM [59, 83] , while it was not observed after prolonged exposure [83] . The stimulation of Dectin-2 receptor with ManLAM induced the production of both pro-and anti-inflammatory cytokines according to its presentation (soluble/plate coated) [66] .
Glycolipid purification procedures impact on the elicited immune response
Several procedures have been described by different laboratories for the purification of LAM and other mycobacterial glycolipids [74, 84] . Generally, these procedures rely on the initial extraction from dried bacterial cells or cell walls with a lipophilic organic solvent/water system, followed by hydrophobic interaction and size exclusion chromatography in the presence of a detergent. These purification methods may result in complex glycolipid fractions of varying compositions that are not limited to mannosylterminated glycolipid species alone. In addition, in many instances the purification procedure used, and most importantly the methods used to control the purity of the preparations are not described.
ManLAM preparations from Colorado State University (CSU) have over the years been used by many investigators, and are regarded as the gold standard. During recent years they have been produced under NIH contracts, as TB Vaccine Testing and Research Materials (TBVTRM). We recently found that some TBVTRM Man-LAM preparations were contaminated with other potent immunomodulary molecules that might affect the biological activity of the preparations [18] . Of two TBVTRM ManLAM lots investigated both were shown to contain PIMs and also some unidentified high molecular weight materials in addition to ManLAM. One TBVTRM lot tested showed a very high content of glucose suggesting contamination with mycobacterial glucans. One fraction was most likely arabinomannan (AM), devoid of most or completely lacking the lipid (acyl) part of ManLAM [18] (Figure 1) .
Altogether the findings of contaminating materials (glucans, PIMs) and potential lack of acylation of the ManLAM in the TBVTRM ManLAM preparation described previously [18] may explain some observations where TBVTRM ManLAM preparations have been used. Thus mycobacterial glucans have been reported to suppress IL-12 production in monocyte-derived DCs [85] . The degree of acylation of mycobacterial glycolipids is important for e.g. the regulation of pro-inflammatory cytokines [14, 43, 86 ] so nonacylated or only partially acylated LAM in a ManLAM preparation might exert a competitory/inhibitory effect on the ManLAM. High levels of contaminating anti-inflammatory PIMs may also compete with or inhibit the effects induced by a particular ManLAM lot (see ahead).
It must also be remembered that all of these studies have in common the introduction of exogenous isolated ManLAM or other glycolipid ligands into essentially hydrophilic in vitro assays; yet, these are all highly amphipathic with varying degrees of aqueous compatibility, an important consideration in explaining contradictory outcomes. Now, with the availability of mutants of Mtb devoid of key structural/immunogenic aspects of LAM and LM, a whole bacterium approach can be applied to these questions [87] .
Conclusion
In conclusion, we here review the profound and divergent effects of the major family of lipoglycans ManLAM, LM and PIMs, on M4s and DCs with regard to cell maturation and cytokine responses, and try to conciliate conflicting reports about the specific properties of these glycolipids. We summarize data showing that the described discrepancies are associated on one hand with differences in glycolipids themselves and/or their preparation, and on the other hand with differences in the cells used in the experiments.
With respect to the glycolipids one should keep in mind the variability in their composition, discrete differences in structure, the use of glycolipids from different bacterial strains and also differences in the protocols used for glycolipid isolation. Part of the discordant views of LAM stem from early experiments where AraLAM (without mannose cap, and a potent inducer of TNF) that in early papers [11, 36, 37] was said to stem from the "avirulent" attenuated H37Ra strain in fact came from a rapidly growing strain. Furthermore in some instances the contradictions may have been caused by the use of LAM preparations that were not sufficiently pure, containing, in addition to LAM, other related biologically active molecules.
ManLAM presents varying degrees of pro-inflammatory capacity, depending on the strain it comes from. ManLAM from the laboratory strain Mtb Erdman shows extremely low or no pro-and anti-inflammatory activity, compared to ManLAM from Mtb H37Rv. Some of the low pro-inflammatory activities reported for certain ManLAM preparations may depend on contamination with e.g. PIMs as a result of the difficulty in separating ManLAM and PIM during the isolation process of ManLAM.
A point seldom recognized is that LAM of whatever flavour, and LM, as we know them chemically, consist of a heterogeneous population and the structures presented (e.g. Figure 1 ) are average representations. Hence, in order to dissect the role of mycobacteria derived molecules in innate immune responses the choice of mycobacterial strain for isolation of the glycolipids is of utmost importance.
It is conceivable that different LAM/PIM ratios in the cell wall of different bacterial strains, and during distinct stages of Mtb infection [47] , may be a crucial factor in determining the differential Mtb stimulation or inhibition of the immune system and thereby be decisive for the emergence and outcome of the disease [7, 16, 18] .
Some of the discrepant results may be explained by differences in the cells that were used, such as differences in maturation (resting or already activated) or receptor equipment (TLR, DC-SIGN, mannose receptor etc). One early publication by Bradbury and Moreno [51] clearly illustrates this, where they examined the action of ManLAM on murine peritoneal and bone marrow derived M4s and found that only the former produced TNF in response to H37Rv ManLAM.
Thus, unless head to head experiments are performed, using the same cells, definitive conclusions are difficult to achieve regarding quantitative and even qualitative differences in maturation and cytokine expression.
It will not be possible or even desirable to achieve full consistency in experiments utilizing lipoglycans and immune cells within this large scientific field. However we think that it is important to be aware of the discrepancies described here to be able to critically compare data from distinct sources, to evaluate the relevance of individual experiments and to design properly future research on LAM and its related molecules. To be able to do so it is important that the glycolipids and cells used in the studies are well characterized and that the methods and protocols for preparation of glycolipids and cells are carefully documented.
